97 related articles for article (PubMed ID: 10406057)
21. Single-hit mechanism of tumour cell killing by radiation.
Chapman JD
Int J Radiat Biol; 2003 Feb; 79(2):71-81. PubMed ID: 12569011
[TBL] [Abstract][Full Text] [Related]
22. In vitro determination of radiation sensitivity parameters for DU-145 prostate cancer cells.
Wang JZ; Rhee JG; Shi P; Stewart RD; Allen Li X
Int J Radiat Biol; 2008 Jun; 84(6):515-22. PubMed ID: 18470750
[TBL] [Abstract][Full Text] [Related]
23. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of stage II non-Hodgkin's lymphoma: analysis of 268 patients].
Wang W; Wang L; Huang Y
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):335-7. PubMed ID: 11783121
[TBL] [Abstract][Full Text] [Related]
25. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin.
Caney C; Singh G; Lukka H; Rainbow AJ
Int J Radiat Biol; 2004 Apr; 80(4):291-9. PubMed ID: 15204706
[TBL] [Abstract][Full Text] [Related]
26. [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Xu RH; Lin TY; Xia ZJ; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):401-3. PubMed ID: 12703998
[TBL] [Abstract][Full Text] [Related]
27. Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.
Aurlien E; Kvinnsland Y; Larsen RH; Bruland ØS
Int J Radiat Biol; 2002 Feb; 78(2):133-42. PubMed ID: 11779363
[TBL] [Abstract][Full Text] [Related]
28. Radiobiological responses for two cell lines following continuous low dose-rate (CLDR) and pulsed dose rate (PDR) brachytherapy.
Hanisch PH; Furre T; Olsen DR; Pettersen EO
Acta Oncol; 2007; 46(5):602-11. PubMed ID: 17562436
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
30. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status.
Williams JR; Zhang Y; Zhou H; Gridley DS; Koch CJ; Russell J; Slater JS; Little JB
Int J Radiat Biol; 2008 Apr; 84(4):253-64. PubMed ID: 18386191
[TBL] [Abstract][Full Text] [Related]
31. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
[TBL] [Abstract][Full Text] [Related]
33. Radiation-induced effects on telomerase in gynecological cancer cell lines with different radiosensitivity and repair capacity.
Kurvinen K; Rantanen V; Syrjänen S; Johansson B
Int J Radiat Biol; 2006 Dec; 82(12):859-67. PubMed ID: 17178626
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
[TBL] [Abstract][Full Text] [Related]
35. [Radiosensitivity detected by "comet" assay in two human tumor cell lines].
Gao YH; Yang WZ; Yan J; Yuan ZY; Liu XF; Xu GZ
Zhonghua Zhong Liu Za Zhi; 2004 Apr; 26(4):217-9. PubMed ID: 15312383
[TBL] [Abstract][Full Text] [Related]
36. Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification.
Sakata K; Satoh M; Someya M; Nagakura H; Oouchi A; Nakata K; Kogawa K; Koito K; Hareyama M; Himi T
Strahlenther Onkol; 2005 Jun; 181(6):385-91. PubMed ID: 15925981
[TBL] [Abstract][Full Text] [Related]
37. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
[TBL] [Abstract][Full Text] [Related]
38. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
[TBL] [Abstract][Full Text] [Related]
39. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F
Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313
[TBL] [Abstract][Full Text] [Related]
40. Primary CNS lymphoma.
Gerstner E; Batchelor T
Expert Rev Anticancer Ther; 2007 May; 7(5):689-700. PubMed ID: 17492932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
